Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1)

Journal of Cellular Physiology

Volumn 210, Issue 3, 2007, Pages 807-818

  Greenaway, James ^a   Lawler, Jack ^b   Moorehead, Roger ^a   Bornstein, Paul ^c   Lamarre, Jonathan ^a   Petrik, Jim ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; THROMBOSPONDIN 1; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; INTERNALIZATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OVARY CELL; OVARY CYCLE; OVARY FOLLICLE DEVELOPMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RAT; REGULATORY MECHANISM; RNA INTERFERENCE; SUBFERTILITY;

ANIMALS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; GENE EXPRESSION REGULATION; GRANULOSA CELLS; MICE; MICE, KNOCKOUT; OVARIAN FOLLICLE; OVARY; PROTEIN BINDING; RATS; RECEPTORS, LDL; RNA INTERFERENCE; THROMBOSPONDIN 1; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS;

EID: 33846598411     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20904     Document Type: Article

References (67)

1. Adams JC, Lawler J. 2004. The thrombospondins. Int J Biochem Cell Biol 36:961-968.
2. Amis SJ, Coulter-Smith SD, Crow JC, Maclean AB, Perrett CW. 2005. Microvessel quantification in benign and malignant ovarian tumors. Int J Gynecol Cancer 15:58-65.
3. Armstrong LC, Bornstein P. 2003. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 22:63-71.
4. Barboni B, Turriani M, Galeati G, Spinaci M, Bacci ML, Forni M, Mattioli M. 2000. Vascular endothelial growth factor production in growing pig antral follicles. Biol Reprod 63:858-864.
5. Bein K, Simons M. 2000. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 275:32164-32173.
6. Berisha B, Schams D, Kosmann M, Amselgruber W, Einspanier R. 2000. Expression and localisation of vascular endothelial growth factor and basic fibroblast growth factor during the final growth of bovine ovarian follicles. J Endocrinol 167:371-382.
7. Bernatchez PN, Rollin S, Soker S, Sirois MG. 2002. Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1. J Cell Biochem 85:629-639.
8. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. 2003. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100:12917-12922.
9. Bornstein P. 1992. Thrombospondins: Structure and regulation of expression. FASEB J 6:3290-3299.
10. Bu G, Marzolo MP. 2000. Role of rap in the biogenesis of lipoprotein receptors. Trends Cardiovasc Med 10:148-155.
11. Castellon R, Hamdi HK, Sacerio I, Aoki AM, Kenney MC, Ljubimov AV. 2002. Effects of angiogenic growth factor combinations on retinal endothelial cells. Exp Eye Res 74:523-535.
12. Cursiefen C, Masli S, Ng TF, Dana MR, Bornstein P, Lawler J, Streilein JW. 2004. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 45:1117-1124.
13. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. 1997. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138:707-717.
14. Detmar M. 2000. Tumor angiogenesis. J Investig Dermatol Symp Proc 5:20-23.
15. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. 2001. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 49:293-305.
16. Emonard H, Bellon G, Troeberg L, Berton A, Robinet A, Henriet P, Marbaix E, Kirkegaard K, Patthy L, Eeckhout Y, Nagase H, Hornebeck W, Courtoy PJ. 2004. Low density lipoprotein receptor-related protein mediates endocytic clearance of pro-MMP-2. TIMP-2 complex through a thrombospondin-independent mechanism. J Biol Chem 279:54944-54951.
17. Ferrara N. 2004. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25:581-611.
18. Folkman J. 1992. The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65-71.
19. Fontana A, Filleur S, Guglielmi J, Frappart L, Bruno-Bossio G, Boissier S, Cabon F, Clezardin P. 2005. Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int J Cancer 116:686-691.
20. Fraser HM, Wulff C. 2001. Angiogenesis in the primate ovary. Reprod Fertil Dev 13:557-566.
21. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. 1998. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336-30343.
22. Godyna S, Liau G, Popa I, Stefansson S, Argraves WS. 1995. Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1. J Cell Biol 129:1403-1410.
23. Gonzalez F, Rueda A, Sevilla I, Alonso L, Villarreal V, Torres E, Alba E. 2004. Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: Relationship to platelet alpha-granule content and primary activation. Int J Biol Markers 19:221-228.
24. Greenaway J, Connor K, Pedersen HG, Coomber BL, LaMarre J, Petrik J. 2004. Vascular endothelial growth factor and its receptor, Flk-1/KDR, are cytoprotective in the extravascular compartment of the ovarian follicle. Endocrinology 145:2896-2905.
25. Greenaway J, Gentry PA, Feige JJ, LaMarre J, Petrik J. 2005. Thrombospondin and vascular endothelial growth factor are cyclically expressed in an inverse pattern during bovine ovarian follicle development. Biol Reprod 72:1071-1078.
26. Guo NH, Krutzsch HC, Inman JK, Shannon CS, Roberts DD. 1997. Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. J Pept Res 50:210-221.
27. Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP. 1999. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 3:147-158.
28. Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K, Ikeda E, Takata S, Kobayashi K, Okada Y. 2002. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 16:219-221.
29. Jia H, Bagherzadeh A, Bicknell R, Duchen MR, Liu D, Zachary I. 2004. Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. J Biol Chem 279:36148-36157.
30. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck NP. 2000. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6:41-48.
31. Jonard S, Robert Y, Dewailly D. 2005. Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries. Hum Reprod 20:2893-2898.
32. Kerbel RS, Kamen BA. 2004. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436.
33. Kwak C, Jin RJ, Lee C, Park MS, Lee SE. 2002. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int 89:303-309.
34. Laithwaite JE, Benn SJ, Marshall WS, FitzGerald DJ. LaMarre J. 2001. Divergent Pseudomonas exotoxin A sensitivity in normal and transformed liver cells is correlated with low-density lipoprotein receptor-related protein expression. Toxicon 39:1283-1290.
35. Lawler J. 2002. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6:1-12.
36. Lawler J, Detmar M. 2004. Tumor progression: The effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 36:1038-1045.
37. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, Hynes RO. 1998. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 101:982-992.
38. Lawler JM, Miao WM, Duquette M, Bouck N, Bronson RT, Hynes RO. 2001. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol 159:1949-1956.
39. Lazic A, Dolmer K, Strickland DK, Gettins PG. 2003. Structural organization of the receptor associated protein. Biochemistry 42:14913-14920.
40. ZD, Bork JP, Krueger B, Patsenker E, Schulze-Krebs A, Hahn EG, Schuppan D. 2005. VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Biochem Biophys Res Commun 334:1049-1060.
41. Manabe N, Goto Y, Matsuda-Minehata F, Inoue N, Maeda A, Sakamaki K, Miyano T. 2004. Regulation mechanism of selective atresia in porcine follicles: Regulation of granulosa cell apoptosis during atresia. J Reprod Dev 50:493-514.
42. Margosio B, Marchetti D, Vergani V, Giavazzi R, Rusnati M, Presta M, Taraboletti G. 2003. Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood 102:4399-4406.
43. Mikhailenko I, Kounnas MZ, Strickland DK 1995. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin. A process facilitated by cell-surface proteoglycans. J Biol Chem 270:9543-9549.
44. Mikhailenko I, Krylov D, Argraves KM, Roberts DD, Liau G, Strickland DK. 1997. Cellular internalization and degradation of thrombospondin-1 is mediated by the amino-terminal heparin binding domain (HBD). High affinity interaction of dimeric HBD with the low density lipoprotein receptor-related protein. J Biol Chem 272:6784-6791.
45. Moestrup SK, Gliemann J, Pallesen G. 1992. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res 269:375-382.
46. Neels JG, van Den Berg BM, Lookene A, Olivecrona G, Pannekoek H, van Zonneveld AJ. 1999. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J Biol Chem 274:31305-31311.
47. Nyberg P, Xie L, Kalluri R. 2005. Endogenous inhibitors of angiogenesis. Cancer Res 65:3967-3979.
48. Nykjaer A, Willnow TE. 2002. The low-density lipoprotein receptor gene family: A cellular Swiss army knife? Trends Cell Biol 12:273-280.
49. Pauli SA, Tang H, Wang J, Bohlen P, Posser R, Hartman T, Sauer MV, Kitajewski J, Zimmermann RC. 2005. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology 146:1301-1311.
50. Petrik JJ, Gentry PA, Feige JJ, LaMarre J. 2002. Expression and localization of thrombospondin-1 and -2 and their cell-surface receptor, CD36, during rat follicular development and formation of the corpus luteum. Biol Reprod 67:1522-1531.
51. Scharovsky OG, Binda MM, Rozados VR, Bhagat S, Cher M, Bonfil RD. 2004. Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance. Clin Exp Metastasis 21:177-183.
52. Sengupta K, Banerjee S, Saxena NK, Banerjee SK. 2004. Thombospondin-1 disrupts estrogen-induced endothelial cell proliferation and migration and its expression is suppressed by estradiol. Mol Cancer Res 2:150-158.
53. Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, Sugisaki Y. 2000. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83:196-203.
54. Strickland DK, Gonias SL, Argraves WS. 2002. Diverse roles for the LDL receptor family. Trends Endocrinol Metab 13:66-74.
55. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, Benjamin LE, Lawler J, Kieran M, Shah A, Kalluri R. 2005. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 102:2934-2939.
56. Tsafriri A. 1995. Ovulation as a tissue remodelling process. Proteolysis and cumulus expansion. Adv Exp Med Biol 377:121-140.
57. Tsukada K, Matsushima T, Yamanaka N. 1996. Neovascularization of the corpus luteum of rats during the estrus cycle. Pathol Int 46:408-416.
58. Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F, Dammacco F. 2003. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 88:176-185.
59. Valdez KE, Cuneo SP, Turzillo AM. 2005. Regulation of apoptosis in the atresia of dominant bovine follicles of the first follicular wave following ovulation. Reproduction 130:71-81.
60. Wang S, Wu Z, Sorenson CM, Lawler J, Sheibani N. 2003. Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn 228:630-642.
61. Wang S, Herndon ME, Ranganathan S, Godyna S, Lawler J, Argraves WS, Liau G. 2004. Internalization but not binding of thrombospondin-1 to low density lipoprotein receptor-related protein-1 requires heparan sulfate proteoglycans. J Cell Biochem 91:766-776.
62. Wiltbank MC, Dysko RC, Gallagher KP, Keyes PL. 1988. Relationship between blood flow and steroidogenesis in the rabbit corpus luteum. J Reprod Fertil 84:513-520.
63. Wulff C, Wilson H, Wiegand SJ, Rudge JS, Fraser HM. 2002. Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 143:2797-2807.
64. Yamamoto M, Ikeda K, Ohshima K, Tsugu H, Kimura H, Tomonaga M. 1997. Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas. Cancer Res 57:2799-2805.
65. Yang Z, Strickland DK, Bornstein P. 2001. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 276:8403-8408.
66. Yano K, Oura H, Detmar M. 2002. Targeted overexpression of the angiogenesis inhibitor thrombospondin-1 in the epidermis of transgenic mice prevents ultraviolet-B-induced angiogenesis and cutaneous photo-damage. J Invest Dermatol 118:800-805.
67. Zimmermann RC, Xiao E, Husami N, Saue MV, Lobo R, Kitajewski J, Ferin M. 2001. Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. J Clin Endocrinol Metab 86:768-772.